Dr. Bradley Discusses Moxetumomab Pasudotox

Edward Bradley, MD
Published Online: Tuesday, July 30, 2013
Edward Bradley, MD, Senior Vice President, Head, Innovative Medicines unit (iMED), MedImmune (the global biologics research and development arm of AstraZeneca), discusses the development of moxetumomab pasudotox.

Moxetumomab pasudotox is a monoclonal antibody made up of an antibody directed at CD22 and Pseudomonas exotoxin. The agent binds to CD22 on the surface of the tumor cell and is incorporated into the cell before the Pseudomonas exotoxin metabolizes, is released, and kills the cell.

In a phase I trial, patients with hairy cell leukemia who had failed previous therapy saw over 90% response rate, with over half being complete responses. Bradley said that the durability of the responses was most striking and that moxetumomab pasudotox was well-tolerated.

Online CME Activities
Free CME from PER
Advances in Next-Generation Sequencing in Precision Oncology: Solid Tumors
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast Cancer
Newer Options on the Horizon for Non-Small Cell Lung Cancer
PARP Inhibitors: Current and Future Options for Breast and Ovarian Cancer
More Reading
$auto_registration$